PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 28, 2000JAMA448 citations

HMG-CoA Reductase Inhibitors and the Risk of Fractures

View Full Paper
CMChristoph Meier

Key Points

  • The aim is to evaluate if statins or other lipid-lowering drugs lower the risk of fractures in individuals aged 50 and above.
  • Population-based, nested case-control analysis utilizing data from the UK General Practice Research Database (GPRD).
  • Comparison of 3940 fracture cases to 23,379 matched control patients based on various factors.
  • Control for body mass index, smoking, physician visits, and use of corticosteroids and estrogen.
  • Current statin use associated with decreased fracture risk (adjusted OR 0.55; 95% CI 0.44-0.69).
  • Fibrates or other lipid-lowering drugs did not significantly lower fracture risk (adjusted ORs 0.87 and 0.76, respectively, with overlapping confidence intervals).

Abstract

CONTEXT: Recent animal studies have suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) increase bone formation, volume, and density. It is unknown whether use of statins is associated with a decreased risk of fractures in humans. OBJECTIVE: To determine whether exposure to statins, fibrates, or other lipid-lowering drugs is associated with reduced bone fracture risk. DESIGN: Population-based, nested case-control analysis. SETTING: The UK-based General Practice Research Database (GPRD), comprising some 300 practices, with data collection from the late 1980s until September 1998. SUBJECTS: Within a base population of 91,611 individuals aged at least 50 years (28,340 individuals taking lipid-lowering drugs, 13,271 untreated individuals with a diagnosis of hyperlipidemia, and 50,000 randomly selected individuals without diagnosis of hyperlipidemia), we identified 3940 case patients who had a bone fracture and 23,379 control patients matched for age (+/-5 years), sex, general practice attended, calendar year, and years since enrollment in the GPRD. MAIN OUTCOME MEASURES: Use of statins, fibrates, or other lipid-lowering drugs in case patients vs control patients. RESULTS: After controlling for body mass index, smoking, number of physician visits, and corticosteroid and estrogen use, current use of statins was associated with a significantly reduced fracture risk (adjusted odds ratio OR, 0.55; 95% confidence interval CI, 0.44-0.69) compared with nonuse of lipid-lowering drugs. Current use of fibrates or other lipid-lowering drugs was not related to a significantly decreased bone fracture risk (adjusted OR, 0.87; 95% CI, 0.70-1.08 and adjusted OR, 0.76; 95% CI, 0.41-1.39, respectively). CONCLUSIONS: This study suggests that current exposure to statins is associated with a decreased risk of bone fractures in individuals age 50 years and older. This finding has a potentially important public health impact and should be confirmed further in controlled prospective trials. JAMA. 2000;283:3205-3210

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Christoph Meier (2000) studied this question.

synapsesocial.com/papers/6a12d7738793652519a6818dhttps://doi.org/10.1001/jama.283.24.3205
Ask AI
Helpful
Bookmark
Share
View Full Paper